WT1 and neuroblastoma: Our results have showed that WT1.1-WT1.5, WT1.6-WT1.9, WT1.10, WT1.11-WT1.12 and WT1.13 isoforms are expressed both in untreated (undifferentiated) and treated (RA) neuroblastoma cells by using two antibodies recognizing different domains of canonical protein, and their expression is significantly increased in the latter cells, suggesting that WT1 isoforms are inversely related to oncogenicity of NB.